ZVRA Q3'26 Earnings: EPS estimate is 0.16 USD

What happened

Zevra Therapeutics is scheduled to report its Q3 2026 results on November 3 after the market closes, with disclosure expected at 4:05 p.m. ET. Analysts estimate revenue of $37.08 million and earnings per share, or profit per share, of $0.16.

Confirmed

Global impact / market context

The estimates set reference points for judging whether Zevra’s reported sales and profit per share meet expectations. A shortfall could raise questions about revenue generation or costs, while stronger results could support confidence in the company’s financial performance; the article gives no actual Q3 results yet.

Analyst inference

The article lists earlier reported revenue and earnings per share alongside estimates, but does not identify what drove those results. For investors, the upcoming comparison between actual figures and estimates may influence views of Zevra’s ability to translate sales into profit and fund its operations.

Analyst inference

What to watch

1. Check the November 3 release after market close for reported revenue against the $37.08 million estimate; the article does not provide the actual Q3 figure yet. Confirmed
2. Compare reported earnings per share, meaning profit per share, with the $0.16 estimate to see whether results meet the stated expectation. Proposed
3. If revenue or profit per share differs from estimates, assess whether the company explains the difference through sales or costs, which could shape views of future performance. Analyst inference

Evidence

• Original source link unavailable